Revisiting the impact of immunoglobulin isotypes in multiple myeloma

Susan Bal; Smith Giri; Kelly N Godby; Luciano J Costa

doi:10.1007/s00277-022-04783-1

Revisiting the impact of immunoglobulin isotypes in multiple myeloma

Ann Hematol. 2022 Apr;101(4):825-829. doi: 10.1007/s00277-022-04783-1. Epub 2022 Feb 9.

Authors

Susan Bal^#¹, Smith Giri^#^{2

3}, Kelly N Godby², Luciano J Costa²

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham, AL, USA. susanbal@uabmc.edu.
² Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham, AL, USA.
³ Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, USA.

^# Contributed equally.

PMID: 35138417
DOI: 10.1007/s00277-022-04783-1

Abstract

Association of immunoglobulin isotypes with survival in the context of modern prognostic factors has not been determined. We utilized the Flatiron Health Electronic Health Record database and identified 8468 MM patients. Compared to IgG MM, patients with IgA MM were more likely to have ISS-III, anemia, and t(4;14), and light chain (LC) MM had higher renal dysfunction and t(11;14). IgA and LC MM patients have an inferior OS. The adverse prognostic impact of IgA and LC isotypes on OS persisted even after adjustment for variables impacting outcomes and likely suggests their unique biology beyond the presence of adverse prognostic factors.

Keywords: Multiple myeloma; Immunoglobulin isotype; Prognosis.

MeSH terms

Humans
Immunoglobulin A
Immunoglobulin Heavy Chains / genetics
Immunoglobulin Isotypes
Immunoglobulin Light Chains
Multiple Myeloma*
Prognosis

Substances

Immunoglobulin A
Immunoglobulin Heavy Chains
Immunoglobulin Isotypes
Immunoglobulin Light Chains